NanoEntek builds its business on lab-on-a-chip technology, which handles sample injection, reaction and measurement all on a single small chip, and makes and sells gene-delivery and cell-analysis instruments as well as diagnostic medical devices and their dedicated consumables. The backbone of the model is that once an instrument is sold, consumables follow it repeatedly. A March 2026 disclosure reported full-year revenue of ₩38.1 billion, operating profit of ₩1.1 billion and net profit of ₩1.6 billion; revenue has grown steadily at double-digit rates, operating profit has turned from loss to profit, and through Q1 the pace of earnings growth outran revenue growth. The point worth watching now: if the added revenue firms up into durable profit, the joint growth in revenue and earnings works as a strength; but because the absolute size of profit is still small, a swing in just one or two cost lines can move the margin sharply, and capital-related disclosures such as a comprehensive stock swap or transfer carry relatively large weight (the trailing P/E of 85x is closer to an optical illusion caused by the small earnings base right after the swing to profit).
At-a-glance assessment financial health · growth · profitability · valuation
- Debt ratio, current ratio and interest burden all look healthy.
- Revenue rose 25.2% year over year, and the pace is quickening (3-year trend: rising).
- Most recent quarter (Q1 2026) revenue was 31.7% higher than a year earlier.
- ROE is 1.7% (controlling-interest basis). It is below the sector average.
- Operating margin is 2.9%.
- The P/E sits above the sector median, reflecting elevated expectations.
Ownership & governance As of 2025-12-31
Largest shareholder A Plus Asset Advisor 25.56% (corporate)
Controlling bloc incl. related parties 41.24%
With the controlling bloc holding 41%, the ownership structure is stable.
🔎 In-depth analysis
- NanoEntek runs its business on lab-on-a-chip technology (a nano-bio convergence technology that handles sample injection, reaction and measurement all on a single small chip).
- It has two main pillars: in biotechnology it makes gene-delivery systems and cell-analysis instruments and their consumables, and in diagnostic medical devices it develops, produces and sells cell-diagnostic and immunodiagnostic instruments and their dedicated consumables.
- Because selling one instrument brings repeated purchases of the matching consumables, the backbone of the model is that consumable revenue accumulates as the installed base of instruments grows.
- As this is a small-cap stock, it is worth tracking, alongside the business trend, the impact of any single disclosure such as financing or changes in share count.
- The latest close is ₩3,590 and the market cap is ₩136.8 billion.
- The price sits below its 20-day line (₩3,936) and below its 60-day line (₩4,878).
- Trading beneath both its short- and medium-term moving averages, the trend is on the soft side.
- The RSI (a supplementary gauge comparing upward and downward strength over the past 14 days on a 0-100 scale) is 36.4, a neutral level.
- The one-month change is -14.7%, the three-month change is -26.3%, and the price sits -53.2% from its 52-week high.
- Relative strength versus the KOSDAQ is 69 (on a 1-99 scale that converts return against the index over the past year while weighting recent performance more heavily; higher means stronger than the market).
- That places it roughly in the top 30% of all stocks for strength.
- Over the past three months it lagged the index by 2.6%.
- Chart reading is best done alongside volume and disclosure dates.
- Recent full-year revenue was ₩38.1 billion, operating profit ₩1.1 billion and net profit ₩1.6 billion.
- The operating margin of 2.9% and ROE (how much the company earns in a year on its equity) of 1.7% are still on the low side, but this should be read together with the fact that these margins are at the start of a recovery, coming right after operating profit turned from a 2023 loss to profit.
- The P/E (the share price as a multiple of one year's earnings) looks high at 85x, but that is not because the stock is expensive; it is because earnings have only just turned positive, so the denominator, earnings itself, is still small.
- At an earnings inflection like this, it is hard to call the stock expensive on a single trailing P/E figure alone, so the pace at which earnings grow should be watched too.
- P/B (the share price as a multiple of book value) is 1.50x, not excessive against asset value.
- On the financial side, a current ratio of 13x, a debt ratio of 107.7% and a healthy interest-coverage ratio mean debt burden and short-term-funding risk are not large.
- Revenue rose year after year, from ₩26.8 billion in 2023 to ₩30.5 billion in 2024 to ₩38.1 billion in 2025, and the pace is quickening (+25.2% in 2025 versus +13.5% the prior year).
- More importantly, operating profit turned from a ₩2.2 billion loss in 2023 to a ₩0.6 billion profit in 2024 and ₩1.1 billion in 2025, completing the swing to profit.
- The trend continued this year: in Q1 2026, revenue rose +31.7%, operating profit +82.7% and net profit +287% year over year.
- As diagnostic-instrument installations grow, the consumable revenue that follows accumulates, and with the cost structure from the loss-making years cleaned up, more of the added revenue appears to be dropping through to profit.
- Revenue is on track to grow again this year over last, and the key question is how well the earnings improvement seen in Q1 is sustained through the year.
- The most recent disclosure, an earnings-change filing on March 16, 2026, reported full-year revenue of ₩38.1 billion, operating profit of ₩1.1 billion and net profit of ₩1.6 billion.
- It is worth checking whether it points the same way as the body's story of rising revenue and positive operating profit, and whether any one-off factors are involved.
- Before that, on October 1 and October 2, 2025 (a corrected filing), there were securities-issuance result reports (comprehensive stock swap and transfer).
- Because this is a swap-and-transfer transaction that affects share count and capital structure, the key is to follow its purpose and whether the subsequent changes in funding and stakes translate into actual business.
- The strengths are clear.
- Revenue is growing steadily at double-digit rates, and after operating profit swung from loss to profit, the pace of earnings growth has outrun revenue growth through Q1, so profitability is improving.
- The financial structure is also stable on debt and liquidity.
- The trailing P/E prints high at 85x, but that is closer to an optical illusion from the small earnings base right after the swing to profit, so it is hard to call the stock overvalued on that number alone.
- On the cautionary side, because the absolute size of profit is still small, a swing in just one or two cost lines can move the margin sharply, and because the market cap is small, capital-related disclosures such as a comprehensive stock swap or transfer carry relatively large weight for share count and the ratios.
- In short, as long as the added revenue firms up into durable profit and capital-related disclosures connect well to the business, the strength of joint revenue-and-earnings growth stays alive; conversely, if the earnings improvement is a one-quarter event or leaned on one-off items, the stock weakens.
🔎 Valuation vs peers Overvalued
Peers with adjacent market capitalizations within the medical, precision and optical instruments sector.
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Synergy Innovation | 48.74x | 0.69x | 1.42% |
| KNR Systems | — | 5.01x | -36.99% |
| M.I.Tech | 6.85x | 1.11x | 16.15% |
We looked first at public-data peers with nearby market capitalizations within medical, precision and optical instruments. The current P/E (the share price as a multiple of one year's earnings) is 86.51x and P/B (the share price as a multiple of book value) is 1.50x. That said, smaller-cap names are heavily affected by earnings swings and financing disclosures, so we did not draw firm conclusions from last year's confirmed-earnings ratios alone. The basis for the outlook box is a DART seasonality approximation.
Earnings outlook company-stated · verified
| Type | Period | Revenue | Operating profit | Net profit |
|---|---|---|---|---|
| This year | 2026 | ₩47.5 billion | — | — |
| Next quarter | Q2 2026 | ₩10.7 billion | — | — |
Price history Close · MA20 · MA60
The latest close is ₩3,590 and the market capitalization is ₩136.8 billion. The price sits below its 20-day moving average (₩3,936) and below its 60-day moving average (₩4,878). It is under both its short- and medium-term moving averages, so the trend looks subdued. The RSI (a supplementary indicator that gauges the strength of gains versus losses over the past 14 days on a 0-100 scale) is 36.4, a neutral level. The one-month change is -14.7%, the three-month change is -26.3%, and the position relative to the 52-week high is -53.2%. Relative strength versus the KOSDAQ is 69 (on a 1-99 scale, converted from returns against the index over the past year with more weight on recent performance; higher means stronger than the market). It is stronger than roughly 70% of all stocks. Over the past three months it lagged the index by 2.6%. Chart interpretation is best done alongside trading volume and the dates on which disclosures occur.
Relative performance stock vs index · start = 100
Excess return vs index · 3M -2.62% / 6M -23.50% / 12M -1.59%
Key metrics vs sector median
Valuation
The P/E of 86.51x is above the sector median (22.72x). The P/B of 1.50x is in line with the sector median (1.61x). That said, this P/E is based on last year's (trailing) results. With recent quarterly earnings up sharply, the trailing P/E can look higher than it really is, so a precise read is best done on this year's expected (forward) earnings.
Enterprise value (EV)
EV = market cap + net debt. It reflects cash and debt, so it captures the real cost of the whole business that market cap alone misses; lower multiples are cheaper relative to earnings or sales.
Profitability & financials
Return on equity (ROE) is 1.7%, below the sector average (5.0%). The operating margin is 2.9%. The debt ratio is 107.7%, so the financial structure is moderate.
Growth FY2025 · annual report (consolidated)
| Item | 2023 | 2024 | 2025 | YoY |
|---|---|---|---|---|
| Revenue | $17.8M | $20.2M | $25.3M | +25.16% ↑ faster |
| Operating profit | -$1.5M | $411,493 | $730,064 | +77.42% |
| Net profit | -$2.4M | $2.4M | $1.0M | -55.93% |
| 5-year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $23.7M | $23.3M | $17.8M | $20.2M | $25.3M |
| Operating profit | $3.5M | $2.9M | -$1.5M | $411,493 | $730,064 |
| Net profit | $4.9M | $3.1M | -$2.4M | $2.4M | $1.0M |
| Revenue CAGR | 4-yr avg 1.60% | ||||
Revenue rose 25.2% year over year (2023 ₩26.8 billion → 2024 ₩30.5 billion → 2025 ₩38.1 billion), and the three-year trend is 'rising'. The pace of growth also quickened from the prior year. Operating profit rose 77.4% year over year. Over the 5 years on record, revenue compound annual growth (CAGR) is 1.6%. The two-year revenue CAGR is 19.2%. In the most recent quarter (Q1 2026), revenue was 31.7% higher than the same period a year earlier.
Latest quarterly results Q1 2026 · vs year-ago
Technical indicators
What stands out
- Revenue grew 25.2% year over year, a sign of growth.
- The balance sheet is stable in terms of debt and liquidity.
Points to watch
- The price is high versus peers, so expectations already appear priced in.
Recent news & events searched · sourced
- 2026-03-16EarningsRevenue or profit-structure change of 30% or more (15% for large corporations): full-year revenue ₩38.1 billion, operating profit ₩1.1 billion, net profit ₩1.6 billionThis is recent confirmed or preliminary results. Check whether it points the same way as the annual trend and whether any one-off factors are involved. Source
- 2025-10-02Update[Corrected] securities-issuance result report (merger, etc.): securities-issuance result report (merger, etc.) 6.0 NanoEntek correction filing (report) October 2, 2025. 1. Filing subject to correction: securities-issuance result report (comprehensive stock swap and transfer). 2. Original filing date of the document subject to correction: October 1, 2025. 3. Correction items: item, reason for correction, before correctionThis disclosure must be read together with the purpose of the incoming funds and the change in share count. Where a facility or operating purpose is stated, the key is whether the investment is actually executed and connects to revenue. Source
- 2025-10-01UpdateSecurities-issuance result report (merger, etc.): securities-issuance result report (merger, etc.) 6.0 NanoEntek securities-issuance result report (comprehensive stock swap and transfer). To the Governor of the Financial Supervisory Service, October 1, 2025. Company name: NanoEntek Co., Ltd. Representative director: Jeong Chan-il. Head-office location: Ace High-End Tower 1, 5 Digital-ro 26-gil, Guro-gu, SeoulThis disclosure must be read together with the purpose of the incoming funds and the change in share count. Where a facility or operating purpose is stated, the key is whether the investment is actually executed and connects to revenue. Source
Figure cross-check computed ↔ external
| Metric | Computed | External | Status | Source |
|---|---|---|---|---|
| Closing price | ₩3,590 | ₩3,590 | Confirmed | link |
| Latest quarterly results | revenue ₩10.5 billion, operating profit ₩0.1 billion | revenue ₩10.5 billion, operating profit ₩0.1 billion | Confirmed | link |
| Full-year results | revenue ₩38.1 billion, operating profit ₩1.1 billion | revenue ₩38.1 billion, operating profit ₩1.1 billion | Confirmed | link |
| Results disclosure source text | revenue30%: revenue ₩38.1 billion · operating profit ₩1.1 billion · net profit ₩1.6 billion | revenue30%: revenue ₩38.1 billion · operating profit ₩1.1 billion · net profit ₩1.6 billion | Confirmed | link |
| Financing disclosure source text | []: 6.0 2025 10 02 1. : 2. : 2025 10 01 3. | []: 6.0 2025 10 02 1. : 2. : 2025 10 01 3. | Confirmed | link |
| Financing disclosure source text | : 6.0 2025 10 01 : : : 26 5, 1 | : 6.0 2025 10 01 : : : 26 5, 1 | Confirmed | link |
| Outlook-box basis | DART | DART | Confirmed | link |
Recent filings
- 2026-05-29Disclosure
- 2026-05-29Shareholders' meeting notice
- 2026-05-15PeriodicQuarterly report
- 2026-05-14Shareholders' meeting notice
- 2026-04-15Disclosure
- 2026-04-15Shareholders' meeting notice
- 2026-03-31Shareholders' meeting notice
- 2026-03-23PeriodicAnnual business report
- 2026-03-20OwnershipOwnership-change filing
- 2026-03-20OwnershipOfficers'/major-shareholders' holdings report
- 2026-03-20Audit report
- 2026-03-16Shareholders' meeting notice
📖 Plain-language glossary — expand if you are new to this
- P/E
- How many times a year's net profit the price is worth (lower is cheaper relative to earnings). The P/E here is on trailing (last full-year) results; for companies whose earnings swing fast (memory chips and other cyclicals/high-growth), a forward P/E on this year's expected earnings is more accurate.
- P/B
- Price relative to net assets (equity). Around 1x means it trades near book value; below 1x means below book.
- P/S
- Price relative to a year's revenue — useful for growth companies with thin earnings.
- Net debt / EV
- Net debt = interest-bearing debt − cash. Negative means more cash than debt (net cash). EV (enterprise value) = market cap + net debt, closer to what it would cost to buy the whole business.
- EV/EBIT · EV/EBITDA · EV/Sales
- Enterprise value against operating profit (EBIT), EBITDA, or revenue. Unlike P/E these reflect debt and cash; lower is cheaper relative to earnings power or sales.
- FCF / FCF yield
- Free cash flow = operating cash − capex, the cash actually left over. FCF yield = FCF ÷ market cap; higher means more cash generated per unit of market value.
- Intrinsic value (DCF)
- Future free cash flow (or, for some capex-heavy but profitable names, forecast earnings) discounted to today to estimate per-share value. Because it shifts a lot with the discount-rate and growth assumptions, it is shown as a bear/base/bull range, and the basis and assumptions are disclosed in one line beneath it.
- ROE
- How much profit the company earns in a year on its equity (%). Higher means better returns on capital.
- EPS / BPS
- Earnings per share / net assets (book value) per share.
- Operating / net margin
- Profit left from the core business / final profit after tax and interest, per unit of revenue.
- Debt ratio
- Debt relative to equity (%). Higher means more reliance on borrowing (norms vary by sector).
- Current ratio
- Assets convertible to cash within a year against debt due within a year. Above 100% leaves some short-term headroom.
- Interest coverage
- How many times operating profit covers the interest owed. Below 1x means operating profit alone struggles to cover interest.
- Dividend yield / payout ratio
- The year's dividend as a % of today's price / the share of earnings paid out as dividends.
- Revenue CAGR
- Multi-year growth expressed as a single yearly average (compound annual growth rate).
- RSI (short-term signal)
- Whether recent price action is overheated or beaten down. Above 70 is overbought, below 30 oversold.
- MA20 / MA60 (moving averages)
- The 20- and 60-day average price. Price above them signals a firmer short-term trend.
- vs 52-week high
- How far below the past year's peak the price sits now (%).
All figures are for reference only; how they read varies by sector and over time.
Sources: Korea FSC market-price API (data.go.kr), OpenDART, KRX/KIND — public data only.
Bong Stocks presents public-data-based information for reference only. It is not investment advice and contains no target prices, ratings, or buy/sell recommendations. Verify independently before making any decision.